Nabila (Memantine)

Memantine, the active ingredient in Nabila, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is used to treat cognitive decline in patients with moderate to severe Alzheimer’s disease. The medication is indicated for patients diagnosed with Alzheimer’s disease who require symptomatic improvement of memory, reasoning and functional abilities.

GNH USA supplies Nabila as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our supply chain adheres to stringent quality standards, ensuring product integrity from manufacturing to delivery.

Memantine is used in the management of Alzheimer’s disease, targeting the glutamatergic pathway to improve cognitive function.

Alzheimer’s disease (moderate to severe): improves cognition, memory and daily functioning in patients with advanced disease. Alzheimer’s disease (mild to moderate) as adjunct therapy: may provide additional benefit when combined with cholinesterase inhibitors. Behavioral symptoms of Alzheimer’s disease: can help reduce agitation and improve overall patient behavior.

Memantine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or imbalance. - Headache: mild to moderate pain in the head. - Constipation: reduced bowel movements or hard stools.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring immediate medical attention. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Hallucinations: visual or auditory disturbances.

When prescribing Memantine, clinicians should consider several precautionary measures to ensure patient safety. - Renal impairment: dose adjustment may be required in patients with reduced kidney function. - Hepatic disease: monitor liver function as metabolism may be affected. - Concomitant use with NMDA antagonists: avoid additive neuro‑psychiatric effects. - History of seizures: use with caution and monitor for seizure activity. - Psychiatric disorders: assess for worsening depression or psychosis. - Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Memantine can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neuro‑psychiatric side effects. - Ketamine: additive NMDA blockade can lead to excessive sedation or cognitive impairment.

Moderate Interactions (Monitor Closely): - Anticholinesterase inhibitors (e.g., donepezil): monitor for altered cognitive response. - Diuretics (e.g., furosemide): may increase risk of renal dysfunction. - CNS depressants (e.g., benzodiazepines): may enhance sedation. - Anticonvulsants (e.g., carbamazepine): may affect memantine plasma levels.